Preventive treatment with Takhzyro (lanadelumab) significantly reduces the number of swelling attacks in people with hereditary angioedema (HAE), even in…
Articles by Inês Martins, PhD
Preventive treatment with Takhzyro (lanadelumab) is effective at delaying and lowering the monthly rate of attacks in a broad…
After showing a sustained reduction in kallikrein levels in animal models, Intellia Therapeutics will be moving forward…
A small molecule inhibitor being developed for hereditary angioedema (HAE) treatment, called PHA121, was as effective as Firazyr (icatibant…
The European Medicines Agency has validated BioCryst Pharmaceuticals‘ application requesting the approval of berotralstat as a once-daily oral…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines…
Patients who experience an angioedema attack during treatment with angiotensin-converting enzyme inhibitors — a kind of medication for high blood pressure…
Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary…
Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces…
The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor [human]) to help prevent angioedema…